Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 20, Issue 6 (November 2018) 20, 615–620; 10.4103/aja.aja_73_18

The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience

Run-Zhuo Ma1, Lei Tian2, Li-Yuan Tao3, Hui-Ying He4, Min Li4, Min Lu4, Lu-Lin Ma1, Hui Jiang1, Jian Lu1

1 Department of Urology, Peking University Third Hospital, Beijing 100191, China
2 Department of Hematology, Peking University Third Hospital, Beijing 100191, China
3 Department of Biostatistics, Peking University Third Hospital, Beijing 100191, China
4 Department of Pathology, Peking University Third Hospital, Beijing 100191, China

Correspondence: Dr. J Lu (lujian@bjmu.edu.cn) or Dr. H Jiang (jianghui55@163.com)

Date of Submission 23-Dec-2017 Date of Acceptance 05-Jul-2018 Date of Web Publication 21-Sep-2018

Abstract

This study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma (PTL) patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for analysis. The Kaplan–Meier method, Log-rank test, and multivariate Cox proportional hazard regression analysis were applied to evaluate progression-free survival (PFS), overall survival (OS), and determine prognosis predictors. The median follow-up time was 30 months. Median OS and PFS were 96 months and 49 months, respectively. In univariate analysis, advanced Ann Arbor stage (III/IV) (P < 0.001), B symptoms (P < 0.001), and extranodal involvement other than testis (P = 0.001) were significantly associated with shorter OS and PFS. In multivariate analysis, Ann Arbor stage was significantly associated with OS (OR = 11.58, P = 0.049), whereas B symptom was significantly associated with PFS (OR = 11.79, P= 0.049). In the 10 patients with the systemic usage of rituximab, bilateral intervention could improve median OS from 16 to 96 months (P = 0.032). The study provides preliminary evidence on bilateral intervention in testes in the rituximab era and validates common prognostic factors for Chinese PTL patients.

Keywords: local treatment modalities; prognostic factors; prophylaxis contralateral orchiectomy; prophylaxis contralateral radiotherapy; testicular lymphoma

Full Text | PDF |

 
Browse:  268
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved